Acetazolamide

Familial periodic paralysis, Calorimetry, Indirect, Hypercapnia + 12 more
Treatment
5 FDA approvals
20 Active Studies for Acetazolamide

What is Acetazolamide

AcetazolamideThe Generic name of this drug
Treatment SummaryAcetazolamide is a medication used to reduce the frequency of absence seizures. It can also be used to treat other types of seizures, like tonic-clonic, myoclonic, and atonic seizures, especially in women whose seizures are linked to their menstrual cycle. However, it may not be effective for long because some patients can become tolerant to its effects. Acetazolamide works by blocking brain carbonic anhydrase, which leads to an increased flow of chloride ions and increased inhibition in the brain.
AcetaZOLAMIDEis the brand name
image of different drug pills on a surface
Acetazolamide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
AcetaZOLAMIDE
Acetazolamide
1978
96

Approved as Treatment by the FDA

Acetazolamide, commonly known as AcetaZOLAMIDE, is approved by the FDA for 5 uses such as Open Angle Glaucoma (OAG) and Other and unspecified effects of high altitude .
Open Angle Glaucoma (OAG)
Other and unspecified effects of high altitude
Altitude Sickness
Open Angle Glaucoma
nonuveitic secondary glaucoma

Effectiveness

How Acetazolamide Affects PatientsAcetazolamide is a medication that helps control fluid production, treats certain types of seizures, and encourages urination when fluid builds up in the body. It is not related to mercury-based diuretics, but is instead a type of sulfonamide drug with a unique structure and effects.
How Acetazolamide works in the bodyAcetazolamide helps with seizures and can also act as a diuretic. It works by inhibiting the carbonic anhydrase enzyme in the brain and kidneys. This reduces the amount of hydrogen ions present, which leads to less carbon dioxide in the lungs and more oxygen. In the kidneys, it reduces the number of hydrogen ions available for active transport, resulting in more bicarbonate, sodium, potassium, and water being excreted from the body.

When to interrupt dosage

The measure of Acetazolamide is contingent upon the diagnosed disorder, including Edema, Tonic - clonic seizures and Metabolic Alkalosis. The amount of dosage fluctuates, as per the administration technique (e.g. Injection, powder, lyophilized, for solution - Intravenous or Powder, for solution) presented in the table below.
Condition
Dosage
Administration
Respiration stimulated
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Urine alkalinization therapy
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Congestive Heart Failure
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Preoperative
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Metabolic Alkalosis
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Open Angle Glaucoma
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Hypercapnia
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
nonuveitic secondary glaucoma
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Swollen feet or ankles
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Familial periodic paralysis
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Calorimetry, Indirect
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Altitude Sickness
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Kidney Calculi
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
salicylate intoxication
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Edema
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Warnings

Acetazolamide has thirteen contraindications, hence it should be avoided if you have any of the conditions mentioned in the table below.Acetazolamide Contraindications
Condition
Risk Level
Notes
Acidosis
Do Not Combine
Angle Closure Glaucoma
Do Not Combine
Disease
Do Not Combine
Cirrhosis
Do Not Combine
depressed sodium and/or potassium blood serum levels
Do Not Combine
Glaucoma
Do Not Combine
Sulfonamides
Do Not Combine
Chronic Kidney Disease (CKD)
Do Not Combine
hyperchloremic acidosis
Do Not Combine
Glaucoma
Do Not Combine
Chronic Kidney Disease (CKD)
Do Not Combine
Addison Disease
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Acetazolamide may interact with Pulse Frequency
There are 20 known major drug interactions with Acetazolamide.
Common Acetazolamide Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Acetazolamide.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Acetazolamide.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Acetazolamide.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Acetazolamide.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Acetazolamide.
image of a doctor in a lab doing drug, clinical research

Acetazolamide Novel Uses: Which Conditions Have a Clinical Trial Featuring Acetazolamide?

Presently, 76 active studies are examining the applicability of Acetazolamide to alleviate Glaucoma, Preoperative Swelling and other related conditions.
Condition
Clinical Trials
Trial Phases
Hypercapnia
0 Actively Recruiting
Familial periodic paralysis
0 Actively Recruiting
Metabolic Alkalosis
0 Actively Recruiting
Edema
0 Actively Recruiting
Preoperative
0 Actively Recruiting
Calorimetry, Indirect
0 Actively Recruiting
Respiration stimulated
0 Actively Recruiting
Congestive Heart Failure
11 Actively Recruiting
Not Applicable, Phase 1, Phase 2
salicylate intoxication
0 Actively Recruiting
nonuveitic secondary glaucoma
0 Actively Recruiting
Urine alkalinization therapy
0 Actively Recruiting
Altitude Sickness
0 Actively Recruiting
Open Angle Glaucoma
10 Actively Recruiting
Phase 3, Not Applicable, Phase 4
Kidney Calculi
0 Actively Recruiting
Swollen feet or ankles
5 Actively Recruiting
Phase 2, Not Applicable, Phase 4

Acetazolamide Reviews: What are patients saying about Acetazolamide?

5Patient Review
4/1/2010
Acetazolamide for Pseudotumor Cerebri
This treatment has been great for me. It's helped with my headaches and neck tension, and I've even lost 16 pounds in 2 1/2 weeks. The only downside is that soda now tastes like metal to me, but that's not really a bad thing!
4.3Patient Review
1/19/2011
Acetazolamide for Pseudotumor Cerebri
I've been taking Acetazpolamide for over two and a half years, and I couldn't be more grateful. Before this medication, I had papilloedema; now, I'm able to live my life normally. Coca-Cola still tastes great to me, too!
4Patient Review
10/9/2010
Acetazolamide for Pseudotumor Cerebri
I had issues with constipation and rectal pain, but this medication cleared that right up. I also experienced less pain overall.
3.3Patient Review
2/3/2010
Acetazolamide for Pseudotumor Cerebri
I had some initial nausea but that went away after a little while. I still have numbness in my hands and feet, though.
3.3Patient Review
5/15/2010
Acetazolamide for Closed Angle Glaucoma
I currently take this medication twice a day, and while it has helped with some symptoms, others (like headaches) are still present. It's an improvement, but not ideal by any means.
3.3Patient Review
3/12/2011
Acetazolamide for Pseudotumor Cerebri
While the side effects are very unpleasant, they have helped to decrease the pressure in my eyes. I'm grateful for that, even though it's not a perfect solution.
2.3Patient Review
11/4/2009
Acetazolamide for Pseudotumor Cerebri
I had an incredibly severe reaction to this medication, to the point where I had to go to the ER instead of going on vacation. If you are sensitive to drugs, I would recommend talking to your doctor about side effects before taking this medication.
2Patient Review
7/1/2009
Acetazolamide for Pseudotumor Cerebri
1.3Patient Review
11/30/2009
Acetazolamide for Pseudotumor Cerebri
I've been on this medication for a decade and, in my opinion, it has saved my vision. The only notable side effect I have experienced is the occasional numbness in my heel.
1.3Patient Review
3/24/2011
Acetazolamide for Pseudotumor Cerebri
I was extremely tired and could not get out of bed. I was put on a high dose because my vision was getting bad quickly, but it was too much too fast. Now I have to get a shunt put in.
1Patient Review
8/7/2009
Acetazolamide for Altitude Sickness
I was taking this medication for a few months and then suddenly started experiencing bruises all over my body for no reason, as well as a sunburn-like rash. My doctor is now trying a new treatment plan with me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about acetazolamide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of drug is acetazolamide?

"The drug acetazolamide falls into the category of anticonvulsants and carbonic anhydrase inhibitors, which are used to treat conditions like glaucoma."

Answered by AI

What are acetazolamide side effects?

"If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

The side effects of the medication may include dizziness, lightheadedness, increased urination, blurred vision, dry mouth, drowsiness, loss of appetite, nausea, vomiting, diarrhea, or changes in taste. These side effects may occur during the first few days as your body adjusts to the medication. If any of these side effects persist or worsen, you should notify your doctor or pharmacist promptly."

Answered by AI

Who should not use acetazolamide?

"Do not use acetazolamide if you are allergic, have severe liver disease, cirrhosis, severe kidney disease, or an electrolyte imbalance"

Answered by AI

What does acetazolamide do to urine?

"Acetazolamide causes an increase in the amount of sodium that is excreted in urine, with only a small, if any, effect on calcium excretion. Acetazolamide has a similar effect of reducing sodium and calcium absorption in the proximal tubule."

Answered by AI

Clinical Trials for Acetazolamide

Have you considered Acetazolamide clinical trials? We made a collection of clinical trials featuring Acetazolamide, we think they might fit your search criteria.Go to Trials
Image of Future Life Clinical Trials in Miami, United States.

Extended vs Immediate Release Torsemide for Heart Failure

18+
All Sexes
Miami, FL
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide. This is a randomized, double-blind, crossover study in patients with heart failure who are on a stable dose of a loop diuretic. During the study period, participants' current loop diuretics will be replaced with an equivalent dose of either immediate-release or extended-release torsemide. Following a one-week stabilization period on the assigned torsemide formulation, patients will report to the clinical site for an assessment visit. On the study day, patients will take a single dose of the same torsemide formulation they have been on for the past week, administered after breakfast. Urine samples be collected are: * 0-4 hours post-dosing (pre-lunch period) * 4-8 hours post-dosing (post-lunch period) * 8-24 hours post-dosing (24 hours period) The primary endpoint will be urinary sodium excretion (4-8 hours after dosing). This will be compared between the extended-release arm and the immediate-release arm to assess the efficacy of prolonged diuretic action. In addition, urinary potassium and creatinine excretion and creatinine clearance will be measured in all urine samples as the safety endpoints.
Phase 4
Recruiting
Future Life Clinical TrialsSalim Shah, PhD, JDSarfez Pharmaceuticals, Inc.
Have you considered Acetazolamide clinical trials? We made a collection of clinical trials featuring Acetazolamide, we think they might fit your search criteria.Go to Trials
Image of Ronald Reagan UCLA Medical Center in Los Angeles, United States.

Next Day Clinic for Patient Care

18+
All Sexes
Los Angeles, CA
The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions \[UVAS\] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.
Recruiting
Has No Placebo
Ronald Reagan UCLA Medical Center
Image of University of Tennessee Medical Center in Knoxville, United States.

Pharmacy Intervention for Medication Adherence

18+
All Sexes
Knoxville, TN
Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.
Recruiting
Senior-friendly
University of Tennessee Medical Center (+1 Sites)Satya Surbhi, PhD
Image of Brigham and Women's Hospital in Boston, United States.

Care Transitions App for Multiple Chronic Conditions

18+
All Sexes
Boston, MA
The objective of this study is to widely implement and evaluate the Care Transitions App in a randomized controlled trial. The app the investigators designed for patients with multiple chronic conditions has four envisioned modules: 1) falls-reduction content, 2) a digital post-discharge transitional care plan (e.g., after hospital care plan, including education, medications, follow-up appointments, warning signs to watch for, nutrition, and other care plan activities), 3) a new module for patients with MCC (diabetes, congestive heart failure, and chronic kidney disease) including condition-specific post-discharge care plans with relevant symptom management activities, 4) a new post-discharge report module which summarizes key care transition findings and allows for patients to enter notes and questions for their providers and their own goals for recovery.
Recruiting
Has No Placebo
Brigham and Women's HospitalLipika Samal, MD, MPH
Image of Saint Luke's Hospital of Kansas City in Kansas City, United States.

Remote Patient Monitoring for Heart Failure

18 - 80
All Sexes
Kansas City, KS
Previous research has investigated the use of remote patient monitoring in various clinical contexts, however there has not been a clinical trial examining use of the VitalCare platform for ambulatory management of heart failure. This trial will serve as a pilot study examining the feasibility of use of the VitalCare platform for ambulatory heart failure management and examine the effect of remote patient monitoring on patient engagement. To the investigators' knowledge, this will be the first study examining the effect of remote patient monitoring with the VitalCare platform on heart failure clinical outcomes, such as hospitalization for heart failure exacerbations and emergency room visits for heart failure.
Waitlist Available
Has No Placebo
Saint Luke's Hospital of Kansas City (+3 Sites)
Have you considered Acetazolamide clinical trials? We made a collection of clinical trials featuring Acetazolamide, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security